Loading…
Neurocrine Biosciences, Inc. is projected to rise to $194.73 by 2027, a +25% move from its current price of $155.83. NBIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $153.41 | $155.82 | $158.27 | -0.01% |
| May 30 | $152.41 | $155.81 | $159.29 | -0.01% |
| May 31 | $151.65 | $155.80 | $160.07 | -0.02% |
| Jun 1 | $151.01 | $155.80 | $160.73 | -0.02% |
| Jun 2 | $150.45 | $155.79 | $161.32 | -0.03% |
| Jun 3 | $149.94 | $155.78 | $161.84 | -0.03% |
| Jun 4 | $149.48 | $155.77 | $162.33 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $149.48 | $155.77 | $162.33 | -0.04% |
| Week 2 | $146.89 | $155.71 | $165.07 | -0.08% |
| Week 3 | $144.92 | $155.65 | $167.18 | -0.11% |
| Week 4 | $143.27 | $155.59 | $168.98 | -0.15% |
| Week 5 | $141.83 | $155.53 | $170.57 | -0.19% |
| Week 6 | $140.53 | $155.48 | $172.01 | -0.23% |
| Week 7 | $139.34 | $155.42 | $173.34 | -0.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurocrine Biosciences, Inc. discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. Its products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI-921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc. (NBIX) presently trades at $156.70 with a market capitalization of $15.76B and a market rank of 682. The current price sits within a bullish context from a technical and forward-looking perspective, and the forecasted path shows substantial upside over the coming years.
The 2026 average is $156.70, reflecting a neutral starting point before the stronger multi-year upside materializes.
A major floor 26.4% below — a decisive break under it would weaken the trend.
The nearest floor, 18.1% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 16.7% above — clearing it would confirm fresh momentum.
Key NBIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $155.69 | Buy | $155.84 | Sell |
| MA 10 | $156.88 | Sell | $154.64 | Buy |
| MA 20 | $149.39 | Buy | $150.11 | Buy |
| MA 50 | $137.85 | Buy | $142.21 | Buy |
| MA 100 | $135.60 | Buy | $139.00 | Buy |
| MA 200 | $139.17 | Buy | $136.80 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.84 | Neutral |
| Stoch RSI (14) | 2.00 | Buy |
| CCI (20) | 50.18 | Neutral |
| Williams %R (14) | -46.80 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | 2.35 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 53.20 | Neutral |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 14.34 | Buy |
| Ultimate (7,14,28) | 47.87 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 155.67 | Buy |
| ADX (14) | 31.67 | Buy |
| ATR (14) | 1.93 | Info |
Technical sentiment is bullish, with RSI(14) at 70. The 50-day simple moving average stands at $136.81 and the 200-day simple moving average at $138.86, framing a constructive near-term trend. Support is identified at $126.32 and resistance at $161.32, offering a defined range for near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $123.10 | $155.83 | $202.74 | 0% | Neutral | |
| $159.08 | $194.73 | $249.51 | +25% | Bullish | |
| $190.47 | $237.40 | $312.13 | +52% | Bullish | |
| $231.01 | $292.30 | $392.31 | +88% | Bullish | |
| $255.48 | $327.57 | $447.43 | +110% | Bullish | |
| $272.44 | $353.54 | $490.42 | +127% | Bullish | |
| $298.21 | $391.31 | $550.45 | +151% | Bullish | |
| $314.13 | $416.51 | $593.40 | +167% | Bullish | |
| $384.25 | $514.52 | $741.71 | +230% | Bullish | |
| $456.46 | $616.96 | $899.20 | +296% | Bullish | |
| $642.12 | $905.06 | $1,381.95 | +481% | Bullish | |
| $1,172.67 | $1,772.39 | $2,900.10 | +10.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $123.10 | $155.83 | $182.01 | +0.00% |
| June 2026 | $131.33 | $153.20 | $182.18 | -1.69% |
| July 2026 | $132.16 | $155.06 | $186.14 | +1.22% |
| August 2026 | $134.03 | $157.96 | $191.00 | +1.87% |
| September 2026 | $132.06 | $156.22 | $190.01 | -1.10% |
| October 2026 | $131.59 | $156.19 | $191.01 | -0.02% |
| November 2026 | $135.70 | $161.55 | $198.49 | +3.43% |
| December 2026 | $137.59 | $164.27 | $202.74 | +1.68% |
Click any year to see its month-by-month NBIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBIX is projected to trade between $123.10 and $202.74, averaging $155.83 — a potential gain of 0% from today's $155.83. Price action looks broadly range-bound.
Neurocrine Biosciences, Inc.'s 2027 outlook centres on $194.73, within a $159.08 to $249.51 range. That is up +25% on the projected 2026 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, NBIX could reach as high as $312.13, with a base case around $237.40 and support toward $190.47 — roughly +52% from $155.83. Momentum favours further upside here.
Expect NBIX to range from $231.01 to $392.31 through 2029. The $292.30 average target implies a +88% move from current prices. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NBIX price prediction for 2030 points to an average of $327.57 (low $255.48, high $447.43) — a potential gain of +110% on today's $155.83. Momentum favours further upside here.
In 2031, NBIX is projected to trade between $272.44 and $490.42, averaging $353.54 — a potential gain of +127% from today's $155.83. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Neurocrine Biosciences, Inc.'s 2032 outlook centres on $391.31, within a $298.21 to $550.45 range. That is up +11% on the projected 2031 average. That marks a +151% change versus current levels. Momentum favours further upside here.
By 2033, NBIX could reach as high as $593.40, with a base case around $416.51 and support toward $314.13 — roughly +167% from $155.83. Buyers look set to stay in control over this stretch.
Expect NBIX to range from $384.25 to $741.71 through 2034. The $514.52 average target implies a +230% move from current prices. That is up +24% on the projected 2033 average. Momentum favours further upside here.
The NBIX price prediction for 2035 points to an average of $616.96 (low $456.46, high $899.20) — a potential gain of +296% on today's $155.83. Buyers look set to stay in control over this stretch.
In 2040, NBIX is projected to trade between $642.12 and $1,381.95, averaging $905.06 — a potential gain of +481% from today's $155.83. That is up +47% on the projected 2035 average. Momentum favours further upside here.
Neurocrine Biosciences, Inc.'s 2050 outlook centres on $1,772.39, within a $1,172.67 to $2,900.10 range. That is up +96% on the projected 2040 average. That marks a +10.4x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NBIX today (≈ 6.41725 NBIX) could be worth
$11,373.85
+$10,373.85 (+1037%) by 2050 · US Dollar
Based on the average projected NBIX price of $1,772.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBIXwould be worth at today's price.
$1,000 invested in NBIX on May 27, 2025 (≈ 8.153947 NBIX) would be worth
$1,270.63
+$270.63 (+27.1%) today · 1.27× · US Dollar
Based on a NBIX entry price of $122.64 vs. today's $155.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $154.67 | $1,007.5 | +0.7% |
| 1 month ago | $128.04 | $1,217.04 | +21.7% |
| 3 months ago | $130.64 | $1,192.82 | +19.3% |
| 6 months ago | $152.16 | $1,024.12 | +2.4% |
| 1 year ago | $122.64 | $1,270.63 | +27.1% |
| All time (5.0y) ago | $94.9 | $1,642.04 | +64.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBIX forecast.
Our base-case forecast reaches $310.00 around 2030.
Implied market cap at $310.00: $31.17B
The multi-year forecast shows a bullish trajectory from 2027 onward, with rising average prices and expanding upside. The 2027 forecast lists an avg of $197.11 and ROI of 25.8, followed by higher averages each year and a continued bullish sentiment through 2050. By 2030, the avg is $333.94 with ROI of 113.1; 2040 sees an avg of $935.59 and ROI of 497.1; and by 2050 the avg is $1,822.84 with ROI of 1063.3.
The min/max paths widen substantially along the horizon, culminating in a 2050 range of $1,205.94 to $2,982.91. These figures illustrate substantial upside but remain subject to market conditions and other real-world factors; they are estimates, not guarantees, and should not be construed as financial advice.
Tap a question to reveal the answer.
In 2030, the forecast shows a 2030 avg of "$333.94" with a min of "$260.40" and a max of "$456.23" and an ROI of 113.1; sentiment is BULLISH.
The forecast turns bullish from 2027 onward, with averages rising to "$197.11" (2027) and continuing up to "$1,822.84" by 2050, with ROI climbing to 1063.3%. The 2026 point is neutral at the average of "$156.70" and ROI of 0.
Yes. By 2040 the avg is "$935.59" and by 2050 the avg is "$1,822.84" with a max of "$2,982.91"; the 2050 min is "$1,205.94". This indicates potential above $1,000 on the forecast path, acknowledging it remains an estimate.
The 2035 forecast lists a min of "$466.25", an avg of "$630.28", and a max of "$918.76", with an ROI of 302.2 and a BULLISH sentiment.
Current price: "$156.70". Market cap: "$15.76B".
Neurocrine Biosciences, Inc. Community Discussion
0Share your Neurocrine Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.